Schaub M C, Hefti M A, Harder B A, Eppenberger H M
Institute of Pharmacology, University of Zurich, Switzerland.
J Mol Med (Berl). 1997 Nov-Dec;75(11-12):901-20. doi: 10.1007/s001090050182.
Cardiac hypertrophy is characterized by an increase in cell size in the absence of cell division and is accompanied by a number of qualitative and quantitative changes in gene expression. Most forms of hypertrophy in vivo are compensatory or adaptative responses to increased workload resulting from various physiological and/or pathological etiologies. Until severe pathological alterations become apparent, myocytes show no drastic morphological changes. On the level of gene expression, upregulation of the so-called fetal genes, i.e., beta-myosin heavy chain, alpha-skeletal and alpha-smooth muscle actin, and atrial natriuretic factor (ANF) may be observed concomitant with a downregulation of alpha-myosin heavy chain and the Ca pump of sarcoplasmic reticulum. The use of primary cell culture systems for cardiomyocytes as an in vitro model for the hypertrophic reaction has identified a number of different stimuli as mediators of cardiac myocyte hypertrophy. The molecular dissection of the different intracellular signaling pathways involved herein has uncovered a number of branching points to cytosolic and nuclear targets and has identified many interactions between these pathways. The individual administration of these hypertrophic stimuli, i.e., hormones, cytokines, growth factors, vasoactive peptides, and catecholamines, to cultured cardiomyocytes, reveals that each stimulus induces a distinct phenotype as characterized by gene expression pattern and cellular morphology. Surprisingly, triiodothyronine (T3) and basic fibroblast growth factor (bFGF) effect a similar cellular phenotype although they use completely different intracellular pathways. This phenotype is characterized by drastic inhibition of myofibrillar growth and by upregulation of alpha-smooth muscle actin. On the other hand, insulin-like growth factor (IGF) I, a factor promoting muscle cell differentiation, and bFGF, an inhibitor of differentiation, cause completely different cardiomyocyte phenotypes although both are known to signal via receptor tyrosine kinases and have been shown to activate the Ras-Raf-MEK-MAP kinase pathway. However, both IGF-I and bFGF depend on T3 to bring about their typical responses, i.e., T3 is permissive for the action of these two growth factors on the expression of alpha-smooth muscle actin and cell morphology. Most of the hypertrophic stimuli are balanced under normal circumstances in vivo. When this balance is disturbed, however, a pathological heart phenotype may become dominant. Thus the knowledge of signaling pathways and cellular responses triggered by hypertrophic stimuli may be essential for the implementation of therapeutic strategies in the treatment of cardiac hypertrophy.
心肌肥大的特征是在没有细胞分裂的情况下细胞大小增加,并伴有基因表达的许多定性和定量变化。体内大多数形式的肥大是对各种生理和/或病理病因导致的工作量增加的代偿性或适应性反应。在严重的病理改变明显之前,心肌细胞没有明显的形态变化。在基因表达水平上,所谓的胎儿基因,即β-肌球蛋白重链、α-骨骼肌和α-平滑肌肌动蛋白以及心房利钠因子(ANF)的上调可能伴随着α-肌球蛋白重链和肌浆网钙泵的下调。将心肌细胞原代培养系统用作肥大反应的体外模型,已经确定了许多不同的刺激作为心肌细胞肥大的介质。对其中涉及的不同细胞内信号通路的分子剖析揭示了许多通向胞质和核靶点的分支点,并确定了这些通路之间的许多相互作用。将这些肥大刺激物,即激素、细胞因子、生长因子、血管活性肽和儿茶酚胺单独施用于培养的心肌细胞,表明每种刺激物都会诱导出一种由基因表达模式和细胞形态特征所定义的独特表型。令人惊讶的是,三碘甲状腺原氨酸(T3)和碱性成纤维细胞生长因子(bFGF)尽管使用完全不同的细胞内途径,但却产生相似的细胞表型。这种表型的特征是肌原纤维生长受到严重抑制以及α-平滑肌肌动蛋白上调。另一方面,胰岛素样生长因子(IGF)I是一种促进肌肉细胞分化的因子,而bFGF是一种分化抑制剂,尽管两者都已知通过受体酪氨酸激酶发出信号并且已被证明能激活Ras-Raf-MEK-MAP激酶途径,但它们却导致完全不同的心肌细胞表型。然而,IGF-I和bFGF都依赖T3来产生它们的典型反应,即T3对于这两种生长因子对α-平滑肌肌动蛋白表达和细胞形态的作用是必需的。在体内正常情况下,大多数肥大刺激是平衡的。然而,当这种平衡被打破时,病理性心脏表型可能会占主导。因此,了解肥大刺激引发的信号通路和细胞反应对于实施治疗心肌肥大的治疗策略可能至关重要。